Non-COVID Neurological Emergencies: A Silent Killer Going Unnoticed during COVID-19 Pandemic.
Journal of Neurosciences in Rural Practice. February 2021 (Original article); DOI:10.1055/s-0040-1722810
Dr. GOVIND MADHAW
Consultant Neurologist and Head- Neurosciences| Director, Centre for Neurosciences (CNS), Ranchi
“Dr. Govind Madhaw is a distinguished neurologist, renowned for his expertise in accurate diagnosis and strategizing the best possible treatment plan for the patient. He focuses on holistic evaluation and the management of the individual, addressing the person behind the illness rather than just the disease. As the Director of CNS – Centre for Neurosciences, he leads the hospital with a commitment to providing patient-centric, ethical, evidence-based neurological care, aligned with international standards.”
Areas of Expertise:
Neuroimmunology: Multiple sclerosis (MS), NMO, MOG, ADEM, Autoimmune Encephalitis, Meningitis, GBS, CIDP, Myasthenia Gravis, Polymyositis, Dermatomyositis, Vasculitis, Sarcoidosis, Rheumatoid Arthritis, SLE, etc.
Movement Disorders: Parkinson’s Disease, Tremor, Dystonia, Blepharospasm, hemifacial Spasm, Ataxia, Chorea, Myoclonus, Tics etc.
Work Experience
• Ex-Assistant Professor at RIMS, Ranchi, Jharkhand.
• Ex-Consultant, Neurology, Orchid Medical centre Ranchi.
Education:
• DM (Neurology): All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand
• MD (Internal Medicine): Rajendra Institute of Medical Sciences(RIMS),Ranchi, Jharkhand
• MBBS: Rajendra Institute of Medical Sciences (RIMS),Ranchi, Jharkhand
PROFESSIONAL MEMBERSHIPS
- Lifetime member of Indian academy of Neurology (IAN)
- Lifetime member of Movement Disorder Society of India (MDSI)
- Lifetime member of Indian Federation of Neurorehabilitation (IFNR)
- Lifetime member of Functional Neurological Disorder Society (FNDS)
- Member of International Movement Disorder Society (MDS)
- Lifetime member of Association of Physician of India (API)
Tenecteplase and alteplase for thrombolysis of acute ischemic stroke within 4.5 hours:
An efficacy and safety study’ Annals of Indian Academy of Neurology May 2022 (Original article); (accepted); DOI:10.4103/aian.aian_1127_21